We aimed to understand how ubiquinol, also known as coenzyme Q10 (CoQ-10), can impact those suffering from heart failure (HF). To do this, we conducted a thorough review of existing studies, searching databases like MEDLINE and the Cochrane Library for relevant literature.
Throughout our evaluation, we focused on key outcomes: whether CoQ-10 could reduce HF-related mortality, improve patients' exercise capacity, and affect the left ventricular ejection fraction (LVEF). Our analysis included findings from 16 different studies that provided intriguing insights.
Notably, we observed that CoQ-10 was effective in reducing HF-related mortality by an impressive 40%. Additionally, patients taking CoQ-10 reported enhanced exercise capacity, which is crucial for improving their quality of life. However, when it came to the left ventricular ejection fraction, the results were less clear; we found no significant difference, though we acknowledge that further research is needed to fully explore its potential effects in this area.
In summary, CoQ-10 shows promise in supporting heart failure patients by reducing mortality and boosting exercise capacity, but its role related to LVEF still warrants additional exploration.
Reduced heart disease
Most Useful Review
When applied, the main benefits are reduced risk of cardiovascular disease, suppression of free radicals, enhanced mental and physical performance, and improved immunity. Coenzyme can mitigate ultraviolet damage, slowing skin ageing. It is recommended for those over 35 to take ubihonol consistently at 100 mg daily, ideally during or after a meal for best absorption.